| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-050 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 第四届监事会第二十四次会议决议公告 一、监事会会议召开情况 上海阿拉丁生化科技股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日以现场结合通讯方式召开了公司第四届监事会第二十四次会议（以下简称"本 次会议"）。本次会议的通知于 2025 年 6 月 30 日通过书面方式送达全体监事。会 议应出席监事 3 人，实际到会监事 3 人，会议由公司监事会主席姜苏先生主持， 公司其他相关人员列席会议。本次会议的召集、召开程序符合国家有关法律、法 规和《公司章程》、《监事会议事规则》的规定。本次会议的召开程序、表决结果 均合法有效。 二、监事会会议审议情况 本次会议由公司监事会主席姜苏先生主持，经全体监事表决，形成决议如下： 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）审议通过《关于参与竞拍中国科学 ...

Group 1 - The company plans to participate in the auction for an 81.96% stake in Kasmir Holdings, which is held by the Chinese Academy of Sciences Holdings, with a transfer base price of 202 million yuan [1] - The board of directors and the supervisory board will review and approve the relevant proposals on July 4, 2025 [1] - The auction is public, and the results and transaction are uncertain; if the auction is unsuccessful, it will not have a significant impact on the company's existing business, future financial status, and operating results [1]

Core Viewpoint - The announcement provides an update on the conversion results and share changes related to the convertible bonds issued by Shanghai Aladdin Biochemical Technology Co., Ltd, highlighting the limited conversion activity and the adjustments in conversion prices over time [2][10]. Convertible Bond Issuance Overview - The company issued 3.874 million convertible bonds with a total value of RMB 38.74 million, starting from April 12, 2022 [3]. - The initial conversion price was set at RMB 63.72 per share [4]. Conversion Status - As of June 30, 2025, a total of RMB 408,000 has been converted into 11,600 shares, representing 0.008209% of the total shares before conversion [2]. - During the period from April 1, 2025, to June 30, 2025, RMB 3,000 was converted into 185 shares, accounting for 0.000131% of the total shares before conversion [10]. - The remaining unconverted bonds amount to RMB 386,985,000, which is 99.892876% of the total issuance [2][10]. Conversion Price Adjustments - The conversion price has undergone several adjustments, with the latest being RMB 13.39 per share effective from June 5, 2025, following the implementation of the 2024 annual profit distribution plan [7][8]. - The conversion price was adjusted downwards multiple times, with the most recent adjustment from RMB 19.89 to RMB 16.17 per share effective from March 26, 2025 [8]. Redemption Status - As of December 10, 2024, the company had canceled RMB 7,000 worth of convertible bonds following a redemption request [9]. Share Capital Changes - The total share capital increased from 277,385,506 shares to 332,602,199 shares due to a capital increase plan, which involved a distribution of shares to existing shareholders [11]. Additional Information - Investors seeking detailed information about the convertible bonds can refer to the company's prospectus published on March 11, 2022 [11].

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-049 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、可转债发行上市概况 （一）可转债发行上市情况 经中国证券监督管理委员会证监许可〔2022〕72 号文同意注册，公司于 2022 年 3 月 15 日向不特定对象发行了 387.40 万张可转换公司债券，每张面值 100 元，发行总额 38,740.00 万元。 累计转股情况：上海阿拉丁生化科技股份有限公司（以下简称"公司"） 向不特定对象发行可转换公司债券"阿拉转债"自 2022 年 9 月 21 日开 始转股，截至 2025 年 6 月 30 日，"阿拉转债"累计有人民币 408,000 元已转换为公司股票，转股数量为 11,600 股，占"阿拉转债"转股前 公司已发行股份总额的 0.008209%。 未转股可转 ...

Group 1 - The company Shanghai Aladdin Biochemical Technology Co., Ltd. issued a total of 3.874 million convertible bonds, each with a face value of RMB 100, raising a total of RMB 387.4 million [2][4][13] - The net proceeds from the bond issuance, after deducting issuance costs of RMB 14,019,245.28, amounted to RMB 373,380,754.72 [2][13] - The bonds have a term of six years, with a fixed interest rate that increases annually, starting at 0.4% in the first year and reaching 3.0% in the sixth year [3][4][13] Group 2 - The initial conversion price for the bonds is set at RMB 63.72 per share, which is based on the average trading price of the company's stock prior to the bond issuance [4][6] - The company has established a special account for managing the raised funds, ensuring that the funds are used specifically for the intended projects [13][16] - The company reported a net profit of RMB 98.76 million for the year 2024, reflecting a year-on-year increase of 15.07% [14][15] Group 3 - The total investment for the projects funded by the bond issuance is RMB 401.38 million, with RMB 387.4 million sourced from the bond proceeds and RMB 1.398 million from the company's own funds [13] - The company has a credit rating of A+ for the bond issuance, indicating a stable outlook [13] - The company operates in the research reagent manufacturing sector, focusing on high-end chemicals and life sciences, and has established a strong brand presence in the market [14][15]

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 向不特定对象发行可转换公司债券受托管理事 务报告 （2024 年度） 债券受托管理人 （陕西省西安市新城区东新街 319 号 8 幢 10000 室） 2025 年 6 月 声明 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、 《上海阿拉丁生化科技股份有限公司可转换公司债券受托管理协议》（以下简称 "《受托管理协议》"）、《上海阿拉丁生化科技股份有限公司向不特定对象发 行可转换公司债券募集说明书》（以下简称"《募集说明书》"）、《上海阿拉 丁生化科技股份有限公司 2024 年年度报告》等相关公开信息披露文件、第三方 中介机构出具的专业意见等，由本次债券受托管理人西部证券股份有限公司（以 下简称"西部证券"）编制。西部证券对本报告中所包含的从上述文件中引述内 容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和完整 性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以 ...

Core Viewpoint - The credit rating of Shanghai Aladdin Biochemical Technology Co., Ltd. remains stable at A+, reflecting its strong product offerings and financial health, despite facing competitive pressures and operational risks in the research reagent industry [3][5][6]. Company Overview - Shanghai Aladdin specializes in the research reagent manufacturing sector, with a diverse product range across high-end chemistry, life sciences, analytical chromatography, and materials science [5][15]. - The company has a well-established brand, "Aladdin," and has expanded its product offerings through the acquisition of Shanghai Yuan Ye Biological Technology Co., Ltd., which is expected to enhance revenue and profit [5][10]. Financial Performance - As of March 2025, the company's total revenue is projected to reach 1.30 billion, with a net profit of 0.30 billion, showing significant growth compared to previous years [3][4]. - The company's sales gross margin is expected to remain high, with a projected EBITDA margin of 34.26% for 2024 [4][5]. - The asset-liability ratio is low, indicating a strong financial position, with cash assets covering short-term debts effectively [5][6]. Industry Environment - The research reagent industry in China is highly competitive, primarily dominated by foreign enterprises, which poses challenges for domestic companies like Aladdin [5][15]. - The domestic market for research reagents is growing, with increasing R&D expenditure from the government, which is expected to drive demand for locally produced reagents [11][14]. Operational Challenges - The company faces safety and environmental risks due to the nature of its products, which include hazardous chemicals [6][18]. - There are uncertainties regarding the expected returns from ongoing investment projects, as delays in project completion could impact future profitability [7][19]. Future Outlook - The credit rating agency has assigned a stable outlook for the company, anticipating continued growth in its product inventory and sales through its e-commerce platform [5][6]. - The company plans to enhance its R&D capabilities and expand its product range, which is expected to support revenue growth in the coming years [18][19].

Core Points - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., has maintained its credit rating for both the company and its convertible bonds at "A+" with a stable outlook [1][4] - The tracking credit rating was conducted by Zhongzheng Pengyuan Credit Rating Co., Ltd. and the results were published on June 24, 2025 [1][2] - The previous credit rating for the company and its bonds was also "A+" with a stable outlook, indicating consistency in the company's financial health [1][4] Summary by Sections - **Company Credit Rating**: The company's main credit rating remains "A+" with a stable outlook, reflecting its solid financial position [1][4] - **Bond Credit Rating**: The credit rating for the "Aladdin Convertible Bonds" is also maintained at "A+" with a stable outlook, indicating reliability for investors [1][4] - **Rating Agency**: The credit rating was performed by Zhongzheng Pengyuan, which conducted a comprehensive analysis of the company's operational status and related industry [1][4]

前次债券评级：公司主体信用等级为"A+"，评级展望为"稳定"，"阿拉转 债"的信用等级为"A+"。 本次债券评级：公司主体信用等级为"A+"，评级展望为"稳定"，"阿拉转 债"的信用等级为"A+"。 本 次 跟 踪 评 级 报 告 已 于 同 日 刊 载 至 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn）。 上海阿拉丁生化科技股份有限公司 关于"阿拉转债"跟踪信用评级结果的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《上市公司证券发行注册管理办法》、《上海证券交易所科创板股票上市 规则》等有关规定，上海阿拉丁生化科技股份有限公司（以下简称"公司"）委 托信用评级机构中证鹏元资信评估股份有限公司（以下简称"中证鹏元"）对公 司于 2022 年 3 月向不特定对象发行的可转换公司债券（以下简称"阿拉转债"） 进行了跟踪信用评级。 公司前次主体信用评级结果为"A+"，评级展望为"稳定"，"阿拉转债"前 次债券信用评级结果为"A+"，评级机构为中证鹏元，评级时间为 2 ...

上海阿拉丁生化科技股份有限公 司相关债券2025年跟踪评级报告 中鹏信评【2025】跟踪第【487】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授 ...